Racial disparities affecting Black patients with diffuse large B-cell lymphoma.

Daniel Arthur Ermann,Victoria Vardell,Lindsey Fitzgerald,Harsh Shah,Deborah Marie Stephens,Boyu Hu

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.7507

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:7507 Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma, with the majority of patients (pts) achieving long-term survival due to the curative nature of frontline therapy. However, limited data exists regarding presentation and clinical outcomes for underrepresented minorities. In this study, we aimed to evaluate the influence of racial identity on overall survival (OS) outcomes for DLBCL pts. Methods: The National Cancer Database was used to identify DLBCL pts diagnosed from 2004-2018. Demographic and treatment characteristics were compared between racial groups. Kaplan-Meier and Cox regression analyses were used to compare OS between Black and white populations. Multivariate analysis and propensity score matching was performed with adjustment for age, stage, co-morbidity score, median income, and insurance status. Results: Of 223,709 DLBCL pts, 87% were white, 8% Black, and 5% other. As compared to white pts at diagnosis, Black pts were younger (mean 56 years [SD ± 16] vs. 66 years [SD ± 15]), more likely to have ≥1 co-morbidity (33% vs. 27%), be HIV-positive (26% vs. 5%), and have both B-symptoms (40% vs. 30%) and stage IV disease (42% vs. 37%) (All p<0.001). In terms of socioeconomic demographics, Black pts were more likely to be uninsured (8% vs. 3%) and be in the lowest median income quartile (43% vs. 15%), but were more likely to receive treatment at academic centers (50% vs. 36%) (all p<0.001). Both Black and white pts had similar IPI scores at diagnosis and were equally likely to receive multi-agent chemotherapy (77% vs. 77%, p<0.001). With a median follow up of 44.9 months, median OS for all treated HIV-negative DLBCL pts was 109 months (range 21-197). Compared to age-matched white pts, Black pts age ≤ 60 had worse median OS (46 vs. 76 months) along with 5- (73% vs. 75%) and 10-year OS (65% vs. 69%) (all p <0.001). Similar results were seen for Black and white pts between the ages of 61-79, but these differences were not demonstrated for pts ≥80 years old (Table). On multivariate analysis, Black race was independently associated with worse OS (HR 1.06, CI 1.01-1.10, p=0.02). Interestingly, the propensity matched analysis demonstrated no significant OS difference between Black and white pts (median 127 vs. 117 months; HR 1.0, CI 0.94-1.06; p=0.90). Conclusions: We present the largest study to date examining racial disparities in DLBCL. This data demonstrates that Black patients have significantly shorter OS compared to white patients, which persists on multivariate analysis. However, this disparity in survival became nonsignificant when patients are equally matched on surrogate markers of healthcare access such as insurance status and median income. Further studies into examining these racial differences are warranted to optimize care for all DLBCL patients. [Table: see text]

oncology